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SUMMARY
1. Evidence is submitted of the lethal part that vaso-
constriction can play in the development of 'irreversibility'.
2. The deleterious effect, and the irrational basis for the
use, of vasopressor therapy is detailed.
3. The beneficial effects of counteracting the vasocon-
strictor response by destroying nervous pathways and by
means of ganglion-blocking agents is demonstrated.
4. The fallacy of a direct relationship between blood
pressure and tissue flow is indicated.
5. The concept of concenhating on viability rather than
on function as an initial measure by using ganglion-blocking
agents (in addition to blood transfusion) is elaborated.
6. Certain characteristics and effects of these agents are
noted.
7. A small series of 6 ·cases treated is presented.
8. The philosophy that the autonomic nervous system
has outgrown its usefulness to man and represents an evolu-
tionary heritage is suggested.
I should like to thank Dr. M. Barlow and Dr. J. Gottlich fortheir
help in treating some of the cases. I am indebted to Prof. D. J. du
Plessis and Mr. Boris Lewin for reading the manuscript. To
Dr. G. D. ElJiott, Superintendent of Coronation Hospital, I am
grateful for permission to report on the cases treated.
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CHLORPROPAMIDE* (DIABINESE) IN DIABETES, WITH SPECIAL REFERENCE
TO TOLBUTAMIDE-FAILED CASES .
JOSEPH B. HERMAN, B.Sc., M.B., CH.B., and W. P. U. JACKSON, M.D., M.R.C.P.
Diabetic Clinic, Department of Medicine, Groote Schuur Hospital and University of Cape Town
In this age of great therapeutic advances we are witnessing the
apparent paradox ofpharmacological substances-the sulpho-
nylurea drugs-being used for the correction of a physio-
logical aberration such as diabetes on the one hand, and on the
other hand of a physiological agent~ortisone-being used
for the treatment or 'cure' of a variety of inflammatory and
allergic conditions.
With the discovery of insulin it seemed that the final answer
to diabetic treatment was at hand, but as time has gone on it
has become clear that insulin is necessary only in a proportion
of diabetics. In the acute-onset diabetes of the juvenile type,
often associated with ketosis, insulin will largely correct the
physiological abnormality. The maturity-onset type of dia-
betic-who has been shown to have available insulin in his
plasma-is not fundamentally benefited, as far as we know,
by exogenous insulin.
Attempts to correct the hyperglycaemia in diabetes by
drugs other than insulin proved unsuccessful or impracticable
• Produced by the Pfizer Laboratories, of America, under the
trade name Diabinese. We are indebted to Messrs. Pfizer, of
Johannesburg, for initial supplies of this drug.
until the advent of the sulphonylureas. It is problematical
whether the other biochemical abnormalities of diabetes
mellitus are corrected by these pharmacological agents.
In the treatment of diabetes mellitus our aim should be the
search for the biochemical abnormality and its correction.
The sulphonylurea drugs may prove to be a stepping stone in
this direction.
The sintilarity of the chemical structure of the sulphonyl-
ureas is evident from their formulae:
H:aN C> S02NH ' CO· NH· C4H 9
Carbutamide (BZ 55)
CH3 C> S02NH ' CO· NH· C4H 9
Tolbutamide (D 860)
a <=> S02NH' CO· NH· CaH7
CWorpropamide
Carbutamide (BZ55) is generally believed to be too toxic
for routine use. With the replacement of the NHz group by
CH3 (tolbutamide) the toxic effects were greatly diminished,
, !

















Some patients were further examined by an augmented
cortisone tolerance test while remaining on chlorpropamide.
A further 4 acute-onset diabetics who were on insulin were
also given chlorpropamide to determine whether this would
lower the insulin requirement in these cases.
'Excellent' response indicates a reduction of the fasting
blood sugar to within the normal range (under 120 mg. per
100 ml.) and virtual absence of glycosuria. 'Poor' indicates
no apparent effect. 'Partial' indicates some definite effect of
chlorpropamide; although the. blood sugar did not become
quite normal, control may yet be considered very satisfactory
in some of the cases so classified.
Excellent hypoglycaemic response ,was obtained in 24 of the
maturity-onset cases, 'partial' in 17 and 'poor' in 11.
In none of the 4 acute-onset diabetics could the dosage of
insulin be lowered whilst on chlorpropamide.
A composite graph (Fig. 1) gives some idea of the response
to chlorpropamide in the first 24 patients treated by one of us
(J.B.H.).
Relation to previous tolbutamide effect
,Of the 52 maturity-onset patients, 51 had previously had
tolbutamide and 43 had failed to respond to this drug. In the
latter group there were 18 primary tolbutamide failures and
25 secondary failures. The test imposed on chlorpropamide
in this particular trial was therefore a very stringent one. An












but unfortunately the hypoglycaemic activity was also some-
what decreased.
Chlorpropamide is the latest addition to these drugs in
general use. A chlorine radical has replaced the NH2 or CH3
group.
There are many puzzling features connected with the
clinical applications of these drugs. If we consider the
maturity-onset type of diabetes only-why do some patients
in this group respond to the sulphonylureas and others not?
.A proportion of the diabetics who respond satisfactorily to
tolbutamide fail to respond after continued treatment. Why
should this secondary failure occur? Why may patients
re pond to chlorpropamide when tolbutamide has failed
either initially or later? Is there a difference in their action
(or is the apparent difference merely one of absorption and
blood level)?
In this series of cases the clinical effect of chlorpropamide
in diabetes mellitus has been studied and special attention
has been paid to those cases
in which there had been
secondary tolbutamide failure.
The 56 diabetics studied here
were seen at the diabetic
clinic of Groote Schuur Hospi-
tal. Of these, 52 (all but 4) -g~E~'1
were of the maturity-onset
.type, all over 40, years of age. 300
Generally they had been seen ,I
over a period of years and all ~
but one had been treated with 1%
other hypoglycaemic agents ~ 100
previously. ~
The fluctuations in blood
sugar have been observed in
some of the cases over a
period of years (in a few cases
one of us, J.B.H., has ob-
served such fluctuations with
remissions and relapses in the
diabetic state for over 10
years). This has enabled us
to form some idea of com- Fig. 1. Chart showing response of first 24 patients treated with chlorpropamide (fasting blood
parative response to the vari- sugars before and after chlorpropamide)..
.ous hypoglycaemic agents.
The subjects were asked to report for a fasting blood-sugar
estimation (Hagedorn-Jensen method) approximately once a
week. In addition many of them kept records of qualitative
tests of the urine. Chlorpropamide was given in a dosage of
2 tablets (2 x 250 mg.) a day. On rare occasions the dose was
increased to 3 tablets and sometimes it was reduced to 1 a
day.
Where a good hypoglycaemic response had been achieved
on chlorpropam.ide, as indicated by fasting blood-sugar
estimations, a glucose tolerance test was done in some cases.
Previous Insulin
Response to Chlorpropamide
TABLE I. CHLORPROPAMIDE RESPONSE IN
RELATION TO PRIOR EFFECT OF TOLBUTAMIDE
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was prescribed and the dose of the drug reduced. Many of
the patients who showed a good hypoglycaemic response also
experienced increased well-being.
INDIVIDUAL CASES
A summary of 3 case reports will serve to give more informa-
tion about the nature of the response in the individual case.
Case 1 (No. 19 in Fig. 1)
A typical good response was obtained in D.R., a middle-aged
European female, whose remi ions and relap es in diabetes had
been followed over a period of 12 years. Tolbutamide, which had
at first produced an excellent result failed to influence the hyper-
glycaemia on continued treatment. The administration of 2 tablets
of chlorpropamide (0·5 g.) effected a prompt response. A fasting
blood sugar of over 300 mg. per 100 mI. was lowered to less than
100 mg. per 100 mJ. and 2 weeks after starting chlorpropamide
remained at that Iow level. Urine tested 4 times a day remained
sugar free.
Case 2 (No. 20 in Fig. 1)
E.C. is a middle-aged European female in whom fasting blood-
sugar tests over a period of years had always given results between
200 and 300 mg. Before administration of chlorpropamide this
patient was on 20 - 30 units of lente insulin and 4 - 6 tablets of
tolbutamide a day, with fasting blood-sugar levels remaining
consistently between 200 and 300 mg. Chlorpropamide in doses of
2 (later 3) tablets a day for the first time in years brought down the
fasting blood sugar to a near-normal level of (140-150 mg.)
Case 3 (No. 13 in Fig. 1)
R.D., a European male aged 42 years, was seen 2 years pre-
viously on a dose of 60 units of insulin daily. He was found to
have Iow fasting blood-sugar levels, the urine being constantly
sugar-free. Insulin was slowly reduced and after a while stopped;
the fasting blood sugars remained normal for about 2 years,
when hyperglycaemia manifested itself. Three tablets of chlor-
propamide lowered the fasting blood sugar from 240 mg. to
130 mg. and the patient has remained well on 3 tablets a day.
Insulin has not been found necessary
DISCUSSION
In this investigation, chlorpropamide was shown to have a
powerful blood-sugar lowering effect. Oral glucose-tolerance
tests (using 50 g. of glucose), however, whilst the patients
were being treated with chlorpropamide, still showed a


























Primary failure 8 6 4
Secondary failure 11 8 6
Partial response 0 2 0
Maintained control 4 1 1
Not used (on insulin) 1 0 0
24 17 11
Relation to previous administration ofinsulin
More than one-third of our patients had previously been
taking insulin.-Table III makes it clear that there is no
9 Januarie 1960
TABLE m. RESPONSE TO CHLORPROPAMIDE
IN RELATION TO PREVIOUS USE OF INSULIN
TABLE II. RESPONSE TO CHLORPROPAMIDE
IN RELATION TO DURATION OF DIABETES
the 43 tolbutamide failures, and a partial response in a
furtherl14T(TaweIshows a further break-down ofthi
c@orpropamide response in relation to prior tolbutamide
effect.)
Relation to race, sex andbody build
All the patients were White except 3, who were Cape
Coloured. Two of these 3 responded very well to chlorpro-
pamide. There were only 11 males in our series. Less than
one-third of our White patients were considered obese-
illustrating our belief that obese diabetics should be treated
by diet only as far as possible.
Relation to duration ufdiabetes
Table IT indicates that an excellent response is quite likely
even where diabetes has been present for over 10 years.
Fig. 2. Case 17 in Fig. 1. Good response to chlorpropamide, but














apparent difference in response to chlorpropamide in the
two groups. One patient, an obese Coloured female of 60,
was poorly; ontrolled on 90 units of insulin daily, and com-
pletely failed to respond to tolbutamide. Her response to
chlorpropamide is classed as excellent.
Toxic effects
Serious toxic effects were not encountered in this series.
One male patient, who failed to respond, said that attacks
of Meniere's vertigo were more frequent when he was taking
chlorpropamide. A complaint of 'feeling queer', associated
with palpitations, necessitated stopping the drug in 2 cases.
Patients with symptoms of gastric intolerance were able to
continue taking the drug when magnesium trisilicate powder
90
I • IZ
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(e.g. Fig. 2). As found with the earlier sulphonylureas,
therefore, the major effect of chlorpropamide is in the basal
or fasting blood-sugar level, rather than on the disposal of
ingested carbohydrates.
CWorpropamide was found in this series to be frequently
very effective where there was primary or secondary tolbuta-
mide failure (e.g. fO . 19 in Fig. 1). In some instances 1
tablet of chlorpropamide (250 mg.) was more effective than
6 tablets of tolbutamide (3 g.). It would appear unlikely then
that there is a purely quantitative difference in action of these
drugs, but we performed no studies of blood levels.
This series is plainly not large enough to judge the
toxicity of the drug, which has been implicated in the appear-
ance of jaundice in certain cases overseas. Its more powerful
hypoglycaemic effect may .give rise to serious reactions,
though we have seen none.
It would appear that chlorpropamide may be effective in
maturity-onset diabetes, whatever the age, sex or body
build of the patient, whatever the duration of diabetes, what-
ever response there had been to tolbutamide, and whether
or not insulin had been used previously.
Our present practice is to start with tolbutamide (maximum
dose 1 g. 3 times a day) where a sulphonylurea appears
indicated (i.e. in maturity-onset cases in which diet alone has
failed). If the response is not satisfactory, or if secondary
failure Qccurs, a trial of cWorpropamide is made.
SUMMARY
1. The response to chlorpropamide has been assessed in 56
diabetic patients, all but 4 being of maturity-onset type.
2. The drug was satisfactory in a high proportion of cases,
and appears to be particularly useful in patients in whom
there has been primary or secondary tolbutamide failure.
3. 0 serious toxic effects were seen in this series:
We should like to thank Prof. J. E. Kench and his assistants for
their great help.
The work was financed by the University of Cape Town Staff
Research Fund, Messrs. Pfizer, and the South African Council for
Scientific and Industrial Research.
CLINICAL TRIAL OF AMINO-METHYLBENZOL-SULPHONYL-
CYCLOHEXYLUREA ('METAHEXAMIDE') IN DIABETICS AFTER
FAILURE OF TOLBUTAMIDE
1. D. HUSKlSSON, M.B., CH.B. and W. P. U. JACKSON, M.D., M.R.C.P.




Metahexamide* is a sulphonyl urea derivative, N. 3 amino 4
methylbenzol-sulphonyl- Tl-cyclohexylureum, with a structur-
al formula (compared with tolbutamide) as follows:





Like its analo~ues, tolbutamide and chlorpropamide, it is
capable of lowerIng the blood sugar in normal subjects and
in some diabetics; not in diabetes of the juvenile type. Its
breakdown and excretion are slower than with tolbutamide
the blood level being reduced 50% from a maximum in abou~
20 hours.
Toxic Effects in Man
Occasional allergic skin reactions and gastro-intestinal
irritation appeared to be the only effects of metahexamide at
first. Unfortunately, while we were in the process of perform-
ing a clinical trial of this substance, the makers reported that
sev~re he~ati~ disturbances had occurred in some patients
while taking Jt, and consequently they very correctly with-
drew all supplies.
We" report below, briefly and for record purposes our
results until the cessation of the trial. '
• T~e metahexamide and the scientific data thereon were kiJIdly
supJ?hed by Messr~. Hoec.hst Pharmaceuticals of South Africa.
Nonstan Laboratones (Pretoria) also supplied some tablets which
had not been used by the time the trial was discontinued. '
Methods
The patients chosen for the trial had diabetes of maturity-
onset type, had never had ketosis and, except one, were all
over 40. The duration of their diabetes varied from 1 to 20
years, and just over half had received insulin previously. All
cases, however, had failed to respond adequately to both diet
and tolbutamide, so that this trial aimed at being rather a
searching test for metahexamide. .
The subjects were out-patients attending a diabetic clinic
and seen for the most part weekly. Several fasting blood
sugars were estimated iri the weeks before metahexamide
was started, while the patient was taking no drug or was
on tolbutamide only. Urine samples were tested at the
clinic and also by the patient at home. In some cases the
24-hour urine sugar was estimated on several occasions.
Weekly weight records were kept. As discussed previously,l
we consider it essential that a period on no treatment other
than diet should precede the evaluation of an oral drug.
The patients were started on 50 or 100 mg. of metahexamide
and this was increased gradually to a maximunl of 300 mg.,
taken in a single daily dose.
Results
Results are classed as 'success' if the blood sugar is brought
within normal range (though we realize that carbohydrate
tolerance may still be grossly abnormal) and the urine tests
showed 'nil' or 'trace'. A 'partial success' indicates a distinct
imprQvement, and 'failure' no apparent effect at all.
The patients receiving the drug numbered 28, and the
effects are assessed in 27; one patient had to stop therapy
